Adverse Changes. Since the date of filing of the Company’s most recent annual or quarterly report, no event that had or is reasonably likely to have a Material Adverse Effect has occurred.
Appears in 11 contracts
Sources: Equity Line of Credit Agreement (American Picture House Corp), Ordinary Share Purchase Agreement (Akari Therapeutics PLC), Ordinary Share Purchase Agreement (Akari Therapeutics PLC)
Adverse Changes. Since the date of filing of the Company’s most recent quarterly or annual or quarterly report, no event that had or is reasonably likely to have a Material Adverse Effect has occurred.
Appears in 4 contracts
Sources: Common Stock Purchase Agreement (XCel Brands, Inc.), Common Stock Purchase Agreement (GD Culture Group LTD), Common Stock Purchase Agreement (Psyence Biomedical Ltd.)
Adverse Changes. Since the date of filing of the Company’s most recent annual report or quarterly reportreport filed pursuant to the Exchange Act, no event that had or is reasonably likely to have a Material Adverse Effect has occurred.
Appears in 3 contracts
Sources: Common Stock Purchase Agreement (International Media Acquisition Corp.), Common Stock Purchase Agreement (Veea Inc.), Ordinary Share Purchase Agreement (Silexion Therapeutics Corp)
Adverse Changes. Since the date of filing of the Company’s 's most recent annual or quarterly report, no event that had or is reasonably likely to have a Material Adverse Effect has occurred.
Appears in 3 contracts
Sources: Equity Line of Credit Agreement (CTT Pharmaceutical Holdings, Inc.), Equity Line of Credit Agreement (NFiniTi Inc.), Equity Line of Credit Agreement (Tradewinds Universal)
Adverse Changes. Since the date of filing of the Company’s most recent annual or quarterly reportreport filed pursuant to the Exchange Act, no event that had or is reasonably likely to have a Material Adverse Effect has occurred.
Appears in 2 contracts
Sources: Common Stock Purchase Agreement (Pineapple Financial Inc.), Common Stock Purchase Agreement (NewGenIvf Group LTD)
Adverse Changes. Since the date of filing of the Company’s most recent annual or quarterly interim report, no event that had or is reasonably likely to have a Material Adverse Effect has occurred.
Appears in 1 contract
Sources: Ordinary Share Purchase Agreement (Intercont (Cayman) LTD)
Adverse Changes. Since the date of filing of the Company’s 's most recent annual or quarterly reportreport filed pursuant to the Exchange Act, no event that had or is reasonably likely to have a Material Adverse Effect has occurred.
Appears in 1 contract
Sources: Common Share Purchase Agreement (Flora Growth Corp.)